Storia della carriera di Konrad Glund
Precedenti posizioni note di Konrad Glund
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Amministratore Delegato | 01/01/2006 | 30/04/2018 |
| Fondatore | 25/07/1997 | 30/04/2018 | |
Prosidion Ltd.
 Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Corporate Officer/Principal | 01/08/2004 | - |
| Martin-Luther-Universität Halle-Wittenberg | Corporate Officer/Principal | - | - |
| IFB Halle GmbH | Amministratore Delegato | - | - |
| Fondatore | - | - |
Formazione di Konrad Glund
| Martin-Luther-Universität Halle-Wittenberg | Doctorate Degree |
Statistiche
Distribuzione geografica
| Germania | 4 |
| Regno Unito | 2 |
Posizioni
| Chief Executive Officer | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| Aziende private | 2 |
|---|---|
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Health Technology |
| IFB Halle GmbH |
- Borsa valori
- Insiders
- Konrad Glund
- Esperienza
